Dr. Dr. Anita Kremer, Judith Bausenwein, Anna-Luise Bernhardt, Anna Stueven, Miriam Maierhofer, Sascha Kretschmann
Our research group mainly focusses on T-cell based immunotherapy of malignant tumors. The emphasis is thereby placed on intracellular processing mechanisms of MHC class II restricted Antigens and identification of neoantigens in solid Tumors. Furthermore, we are working on both aspects also in the context of autoimmune disease.
Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 2009 Oct 22;114(17):3684-92.
Stevanović S, Griffioen M, Nijmeijer BA, van Schie ML, Stumpf AN, Rutten CE, Willemze R, Falkenburg JH.Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia. 2012 Feb; 26(2):312-22.
Kremer AN, van der Meijden ED, Honders MW, Wiertz EJHJ, Falkenburg JHF, Griffioen M. Endogenous HLA-class-II epitopes that are immunogenic in vivo show distinct behavior towards HLA-DM and its natural inhibitor HLA-DO. Blood. 2012 Oct 18;120(16):3246-55.